Talk Topics this year cover:

  • Importance of CDx for Biologics and Small Molecule Drugs – creating therapeutic and market value for patient-centric treatments
  • Evolving CDx from animal models: From proof of concept (POC) to generating biomarker candidates; drug dosing; and response tracking
  • Informatics for analyzing Big Data sets to develop CDx candidates
  • Regulatory issues to be addressed during development
  • Technologies to identify markers

We welcome researchers in biotechnology organizations ranging from start-up companies to leading-edge suppliers to non-profit institutions and encourage participation on the Program Committee as well as talk submissions. Attendees at this event typically range from Development to Post-Marketing Surveillance in biomarkers (development) and diagnostics (market offerings).

Expected Attendees include (see 2016 Attendee List):

  • VPs in Translational Medicine and related functions
  • Executive/Senior Directors
  • Laboratory and Technology Directors
  • Project Managers (technical, logistical, and transitioning projects to partners)
  • Technology leaders and researchers (assays, platforms, informatics)
  • Researchers in assays, diagnostics (basic, development, validation, execution)
  • Allied VP, Executive/Senior Directors, Directors, and Associates in licensing and regulatory